Table 2.

Evolution of CRTC1 methylation sites during the first month of psychotropic treatment

	Probe ID	β at baseline, median (IQR)	β after 1 month, median (IQR)	p value	FDR p value1
All patients (n = 78)	cg21310814	81.7 (78.5–84.3)	83.7 (81.2–84.9)	0.00005	0.004
	cg07015183	88.3 (87–89.5)	89.1 (88–90.3)	0.0001	0.004
	cg02961385	94.7 (94.2–95.4)	95.2 (94.7–96)	0.0009	0.02
	cg17006757	82.8 (80.4–84.2)	83.7 (82–85.3)	0.003	0.048
	cg22536770	94.1 (93.3–94.7)	94.5 (93.9–95.1)	0.003	0.048
Controls (n = 39)	None
Cases (n = 39)	cg07015183	88.3 (87–89.5)	89.1 (88–90.3)	0.0006	0.02
	cg12034943	7.4 (6.4–8.4)	7.2 (6.5–8)	0.0007	0.02
	cg17006757	82.8 (80.4–84.2)	83.7 (82–85.3)	0.0008	0.02

Only the sites with significant changes during the first month of treatment are shown. Of note, all significant methylation sites presented in this table are localized in the gene body region of CRTC1

β at baseline refers to methylation levels before starting the current psychotropic treatment

β at first month refers to methylation levels after one month of treatment with psychotropic treatment

Controls indicate patients whose weight remained stable during the first month of treatment

Cases indicate patients with important (≥5%) early weight gain during the first month of treatment

p values were calculated using paired t-tests. Probes are sorted by significance

¹p values were adjusted using the false discovery rate approach

None: No site with significant change during the first month was observed in control patients